Valganciclovir for CMV prophylaxis in paediatric transplant recipients.

被引：0
|
作者：
Wiesmayr, S
Stelzmueller, I
Jungraithmayr, T
Mark, W
Larcher, C
Margreiter, R
Zimmerhackl, L
Bonatti, H
机构：
[1] Med Univ Innsbruck, Dept Pediat, Innsbruck, Austria
[2] Med Univ Innsbruck, Dept Gen & Transplant Surg, Innsbruck, Austria
[3] Med Univ Innsbruck, Inst Hyg & Microbiol, Innsbruck, Austria
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2005年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
781
引用
收藏
页码：355 / 355
页数：1
相关论文
共 50 条
  • [1] Valganciclovir as CMV prophylaxis in pediatric transplant recipients.
    Bonatti, H
    Wiesmayr, S
    Junngraithmayr, TC
    Margreiter, R
    Zimmerhackl, LB
    [J]. PEDIATRIC TRANSPLANTATION, 2005, 9 : 98 - 98
  • [2] Valganciclovir is effective prophylaxis for CMV in high risk renal transplant recipients.
    Baillie, GM
    Ashcraft, EE
    Taber, DJ
    Stone, SS
    Emovon, O
    Rogers, J
    Afzal, F
    Lin, A
    Rajagopalan, PR
    Baliga, PK
    Chavin, KD
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 377A - 377A
  • [3] A prospective trial of valganciclovir prophylaxis for cytomegalovirus (CMV) prevention in lung transplant recipients.
    Humar, A
    Kumar, D
    Preiksaitis, J
    Fenton, J
    Nia, S
    Jackson, K
    Chernenko, S
    Lien, D
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 270 - 270
  • [4] Ganciclovir vs. valganciclovir for CMV prophylaxis in solitary pancreas transplant recipients.
    Rea, DJ
    Kudva, YC
    Larson, TS
    Stegall, MD
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 380 - 380
  • [5] Increased Incidence of Leucopenia With FDA Approved Valganciclovir Dosing for CMV Prophylaxis in Pediatric Kidney Transplant Recipients.
    Bhatnagar, S.
    Palma, K.
    Palmer, J.
    Baluarte, J.
    Amaral, S.
    [J]. TRANSPLANTATION, 2014, 98 : 501 - 501
  • [6] Comparison of Outcomes in Heart Transplant Recipients Receiving CMV Prophylaxis with CMV IVIG with Valganciclovir versus Valganciclovir Alone
    Moss, I.
    Brueckner, A.
    Rumore, A.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S480 - S480
  • [7] Valganciclovir for CMV prophylaxis in liver transplant recipients: An initial experience.
    Berkman, SC
    Ashcraft, E
    Baillie, GM
    Taber, D
    Lin, A
    Rogers, J
    Baliga, P
    Chavin, KD
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 358 - 358
  • [8] CMV Viremia after Discontinuation of Valganciclovir Prophylaxis in Lung Transplant Recipients
    Gift, T.
    Palafox, J.
    Jones, K.
    Imburgia, T.
    Astor, T.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S485 - S485
  • [9] Comparison of Outcomes in Heart Transplant Recipients Receiving CMV Prophylaxis with CMV IVIG with Valganciclovir versus Valganciclovir Alone
    Moss, I.
    Rumore, A.
    Brueckner, A.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S115 - S116
  • [10] A prospective assessment of valganciclovir for the treatment of cytomegalovirus (CMV) infection and disease in transplant recipients.
    Humar, A
    Moussa, G
    Mazzulli, T
    Siegal, D
    Kumar, D
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 385 - 385
12345